Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Ascitic Drain Insertion And Management in Gynaecology (1077)
Announcements and latest updates

Right Decision Service newsletter: September 2024

Welcome to the Right Decision Service (RDS) newsletter for September 2024.

1.Business case for permanent provision of the Right Decision Service from April 2025 onwards

This business case has now been endorsed by the HIS Board and will shortly be submitted to Scottish Government.

2. Management of RDS support tickets

To balance increasing demand with available capacity and financial resource, the RDS team and Tactuum are now working together to  implement closer management of support tickets. As a key part of this, we want to ensure clear, timely and consistent communication with yourselves as requesters.  

Editors will now start seeing new messages come through in response to support ticket requests which reflect this tightening up and improvement of our processes.

Key points to note are:

2.1 Issues confirmed by the RDS and Tactuum teams as meeting the critical/urgent and high priority criteria will continue to be prioritised and dealt with immediately.

Critical/urgent issues are defined as:

  1. The Service as a whole is not operational for multiple users. OR
  2. Multiple core functions of the Service are not operational for multiple users.

Example – RDS website outage.

Please remember to email ann.wales3@nhs.scot and his.decisionsupport@nhs.scot with any critical/urgent issues in addition to raising a support ticket.

High priority issues are defined as:

  1. A single core function of the Service is not operational for multiple users. OR:
  2. Multiple non-core functions of the Service are not operational for multiple users.

Example – Build to app not working.

2.2 Support requests that are outwith the warranty period of 12 weeks since the software was originally developed will not be automatically addressed by Tactuum. The RDS team will consider these requests for costed development work and will obtain estimate of effort and cost from Tactuum for priority issues.

2.3 Support tickets for technical issues that are not classified as bugs will not be automatically addressed by Tactuum. The definition of a bug is ‘a defect in the software that is at variance with documented user requirements.’  Issues that are not bugs will also be considered for costed development work.

The majority of issues currently in support tickets fall into category 2 or 3 above, or both.

2.4 Non-urgent requests that require a deployment (i.e a new release of RDS) will normally be factored into the next scheduled release (currently end of Nov 2024 and end of Feb 2025) unless by special agreement with the RDS team.

Please note that we plan to move in the new year to a new system whereby requests all come to an RDS support portal in the first instance and are triaged from there to Tactuum when appropriate.

We will be organising a webinar in a few weeks’ time to take you through the details of the current support processes and criteria.

3. Next scheduled deployment.

The next scheduled RDS deployment will take place at the end of November 2024.  We are reviewing all outstanding support tickets and feature requests along with estimates of effort and cost to determine which items will be included in this deployment.

We will update you on this in the next newsletter and in the planned webinar about support ticket processes.

4. Contingency arrangements for RDS

Many thanks to those of you who attended our recent webinar on the contingency arrangements being put in place to prevent future RDS outages as far as possible and minimise impact if they do occur.  Please contact ann.wales3@nhs.scot if you would like a copy of the slides from this session.

5. Transfer of CKP pathways to RDS

The NES clinical knowledge pathway (CKP) publisher is now retired and the majority of pathways supported by this tool have been transferred to the RDS. Examples include:

NHS Lothian musculoskeletal pathways

NHS Fife rehabilitation musculoskeletal pathways

NHS Tayside paediatric pathways

6. Other new RDS toolkits

Include:

Focus on frailty (from HIS Frailty improvement programme)

NHS GGC Money advice and support

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

To go live imminently:

  • Focus on dementia
  • NHS Lothian infectious diseases toolkit
  • Dumfries and Galloway Adult Support and Protection procedures
  • SIGN guideline – Prevention and remission of type 2 diabetes

 

7. Evaluation projects

We have recently analysed the results of a survey of users of the Scottish Palliative Care Guidelines toolkit.  Key findings from 61 respondents include:

  • Most respondents (64%) are frequent users of the toolkit, using it either daily or weekly. A further 25% use it once or twice per month.
  • 5% of respondents use the toolkit to deliver direct patient care and 82% use it for learning
  • Impact on practice and decision-making was rated as very high, with 80% of respondents rating these at a 4-5 on a 5 point scale.
  • Impact on time saving was also high, with 74% of respondents rating it from 3-5.
  • 74% also reported that the toolkit improved their knowledge and skills, rating these at 4-5 on the Likert scale

Key strengths identified included:

  • The information is useful, succinct, and easy to understand (31%).
  • Coverage is comprehensive (15%)
  • All information is readily accessible in one place and users value the offline access via mobile app (15%)
  • Information is reliable, evidence-based and up to date (13%)

Users highlighted key areas for improvement in terms of navigation and search functionality. The survey was very valuable in enabling us to uncover the specific issues affecting the user experience. Many of these can be addressed through content management approaches. The issues identified with search results echo other user feedback, and we are costing improvements with a view to implementation in the next RDS deployment.

8.RDS High risk prescribing (polypharmacy) decision support embedded in Vision and EMIS primary care E H R systems

This decision support software, sponsored by Scottish Government Effective Prescribing and Therapeutics Division,  is now available for all primary care clinicians across NHS Tayside. Board-wide implementation is also planned for NHS Lothian, and NHS GGC, NHS Ayrshire and Arran and NHS Dumfries and Galloway have initial pilots in progress. The University of Dundee has been commissioned to evaluate impact of this decision support software on prescribing practice.

9. Video tutorials for RDS editors

Ten bite-size (5 mins or less) video tutorials for RDS editors are now available in the “Resources for providers of RDS tools” section of the RDS.  These cover core functionality including Save and preview, content page and media management, password management and much more.

10. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Wednesday 23rd October 4-5 pm
  • Tuesday 29th October 11 am -12 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

 

Ascitic Drain Insertion And Management in Gynaecology (1077)

Warning

Objectives

To describe the indications, procedure and monitoring required for the safe insertion of Ascitic Drains in gynaecology including post insertion monitoring

Scope

Women attending with Ascites to Gynaecology where management with Paracentesis Drain is considered

Audience

All healthcare professionals involved in the care of women with ascites who require insertion of Ascitic drain in the gynaecology setting

Please report any inaccuracies or issues with this guideline using our online form

Malignant ascites is the accumulation of fluid within the peritoneal cavity of the abdomen secondary to cancer (an exudate not a transudate). Within gynaecology, ascites is most commonly associated with those suffering with ovarian malignancy. Approximately 60% of patients with advanced ovarian cancer develop ascites necessitating hospital admission and treatment.

The symptoms associated with ascites can be distressing for the patient including abdominal distension and pain, breathlessness, nausea, vomiting, early satiety, constipation and peripheral oedema.  These can greatly impact on patients’ quality of life. 

The principle for management of malignant ascites should be aimed at symptomatic relief and improvement of quality of life. For most patients, paracentesis is the treatment of choice and relieves symptoms in up to 90% patients. It is most likely to relieve symptoms of abdominal distension/discomfort and dyspnoea, however less likely to improve the associated symptoms of peripheral oedema, fatigue and poor mobility.

Paracentesis is a simple procedure to remove ascitic fluid from the abdominal cavity, which can be performed as a day case or as an inpatient. Removal of 4–6 litres is usually enough to give symptomatic relief. Removal of more than 4-6 litres increases the risk of hypovolemia and adverse effects, but may give symptomatic relief for longer until the ascites re-accumulates.   

Paracentesis may not be appropriate if the prognosis is very short and the patient is rapidly deteriorating. 

Indications for drainage of ascites by abdominal paracentesis

  1. As a diagnostic procedure to determine the cause of ascites and ascertain cytological diagnosis. It should be kept in mind there are other causes of ascites other than malignancy. It can be helpful to also send ascites to microbiology and biochemistry. It can be useful to have a serum to-ascites Albumin Gradient (SAAG) if the ascites turns out not to be malignant.
  2. As a therapeutic procedure: in patients with large volume ascites to provide symptomatic relief.

Contraindications

  • Severe bowel distension
  • Severe coagulopathy
  • Disseminated intravascular coagulation
  • Local or systemic infection
  • Low white cell count / neutropenia
  • Skin infection at the proposed puncture site 
  • Distressed/uncooperative patient

Risks with Paracentesis

The risk associated with paracentesis can be associated with the removal of large volumes (> 6 litres) as this can cause a ‘fluid shift’ with resultant hypovolaemia and hypotension, leading to symptoms of dizziness, fatigue and malaise. Additional procedural risks include; perforation of abdominal viscus, haemorrhage, infection, discomfort. See appendix 1 for risks to be discussed with patient when consenting for procedure.

Ultrasound imaging (USS)

Drain insertion should be performed under ultrasound guidance or following marking.  Care should be taken particularly if ascitic fluid is not easily clinically identified, there has been difficulty with previous paracentesis, there is suspected loculation of ascites or there are concerns about bowel obstruction.  Consideration should be given to assistance from radiology department where difficulty is anticipated.

Pre-procedure

  • Review up to date FBC, coag, U+Es and LFTs
  • Check IV access sited and patent
  • Ensure site has been marked if USS guidance not available
  • Ensure nursing staff available to assist insertion
  • Obtain informed consent
  • Patient should empty bladder prior to procedure
  • Check full set of observations including – pulse, BP, temperature, respiratory rate and O2 saturations
  • Ensure correct equipment available – see appendix 2 for required equipment

Procedure

  • Place patient in semi upright position
  • Confirm the presence of ascites
  • The usual site for paracentesis is the left side but can be in either iliac fossa at least 10cm from midline or suprapubically (must ensure bladder is empty). The chosen site should avoid: distended bowel or bladder and inferior epigastric arteries. Guided by ultrasound marking if trained.

  • Abdomen is prepared with aseptic solution and sterile drape applied
  • Infiltrate up to 10ml of 2% lidocaine into the area to be cannulated.
  • Using local anaesthetic syringe, needle is inserted through sheath and ascites withdrawn. A larger needle may need to be considered in patients with a high BMI
  • When anaesthesia of insertion site achieved small incision made with scalpel and drain needle inserted. Once flashback is visualised, advance the catheter whilst withdrawing the needle.
  • If cytology required minimum 200ml should be sent
  • It can be useful to consider sending fluid to microbiology and biochemistry, particularly where the ascites turns out not to be malignant. Tests should include  Cell count and differential, Bacterial culture, Albumin (for serum-to-ascites albumin gradient (SAAG)), Total protein, Glucose and LDH.
  • Closed drainage system is attached.
  • If drain is to remain in situ sutures are inserted and sterile dressing applied.
  • Document the procedure, plan for drainage and required frequency of observation in the notes.
  • Record full set of observations again and volume drained immediately post procedure

Post insertion management of paracentesis drain

  • Record BP, pulse and temperature every 15 minutes for the first hour after insertion, hourly for 4hrs and 4 hourly thereafter if within normal limits
  • Monitor fluid balance and urea and electrolytes daily Observe paracentesis insertion site and change dressing daily.
  • If the patient becomes unwell, clamp the drain, take pulse, blood pressure and temperature and seek medical advice.
  • Aim to remove drain after 48hrs. If continuing to drain significant volumes discuss with medical staff regarding timing of removal

Drainage rate and amount

Most patients will tolerate the procedure well. Total amount drained will depend on the individual patient, the volume of ascites and previous experiences with paracentesis. 

Patient group

Rate

Fluids

Systolic BP >100

No relevant co-morbidites

Drain 1L every 2-4hrs

Max 6L in 24hrs

Not usually required

Systolic BP <100 prior to or during drainage

Cardiovascular or renal comorbidities (at medical staff instruction)

Drain 1L every 4hrs

Max 6L in 24hrs

If BP drops significantly or symptoms of hypovolaemia* - stop drainage and seek medical advice

Consider fluid replacement with IV crystalloid

*Signs and symptoms of hypovolaemia: high pulse, low BP; dizziness; increasing fatigue and malaise.

The drain should be clamped after each litre drained and removed once minimal volumes draining. If significant volumes still draining at 48hrs discuss with senior medical staff regarding keeping the drain in situ for ongoing drainage, this should be reviewed by a senior clinician every 24hrs.

For patients where chemotherapy is unlikely to be effective and who require repeated drainage, an indwelling catheter should be considered and should be discussed with the oncology team.

Editorial Information

Last reviewed: 23/03/2023

Next review date: 31/03/2028

Author(s): Dr Morton Hair, Consultant Gynaecologist.

Version: 1

Approved By: Gynaecology Clinical Governance Group

Document Id: 1077